News & Views
Licensing Agreement Option Activated By Partner Company
Feb 23 2019
Moderna has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers developed by Avacta Group against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
In 2015, Avacta and Moderna formed a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta’s Affimer technology for certain collaboration targets and the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialise Affimers selected by Moderna.
Under the terms of the agreement Avacta may receive undisclosed payments upon future clinical development milestones and royalties in connection with future product sales.
Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development. We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan